8-K current report · filed Nov 3, 2026

PTC THERAPEUTICS, INC. (PTCT) 8-K Current Report: November 3, 2026

Item 7.01Item 8.01Item EX-99.1PTCT overview

Short answer

PTC THERAPEUTICS, INC. (PTCT) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Board-authorized share repurchase program announced November 3, 2026.

PTC THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Board-authorized share repurchase program announced November 3, 2026
  • Potential shareholder return support and reduced share count, with program terms in Exhibit 99.1

Item 8.01 · Other Events

  • Board-authorized share repurchase program of up to $500.0 million
  • Potentially supports per-share value and signals management confidence in the company’s valuation
  • Repurchases discretionary, with timing and execution dependent on market conditions
  • Multiple methods permitted, including open-market, privately negotiated, and accelerated repurchases

Item EX-99.1 · Exhibit EX-99.1

  • Board authorization for up to $500 million in common-stock repurchases, subject to market conditions
  • Repurchases may include open-market purchases, trading plans, privately negotiated transactions and accelerated share repurchases
  • Capital allocation signals management views PTCT shares as undervalued while retaining funding flexibility for pipeline programs and business development
  • Share count reduction could support per-share value, but authorization does not guarantee purchases or specify timing

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PTC THERAPEUTICS, INC. 8-K filings

Get the next PTCT 8-K as it lands

Follow PTCT for push alerts, or ask the research agent what this filing means.